日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

CEACAM5 (Tusamitamab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號:
    CSB-RA005165MB3HU
  • 規(guī)格:
    ¥83486
  • 其他:

產(chǎn)品詳情

  • 產(chǎn)品描述:
    CEACAM5(Tusamitamab Biosimilar Antibody)重組單克隆抗體是一種靶向癌胚抗原相關(guān)細胞黏附分子5(CEACAM5),其別名為癌胚抗原抗體、CD66e抗體、CEA抗體等,對應多種數(shù)據(jù)庫編號及分子名稱。該抗體以重組人CEACAM5蛋白制備,具有高度特異性,種屬反應性經(jīng)驗證適用于食蟹猴(Cynomolgus)模型。 Tusamitamab Biosimilar Antibody作為靶向CEACAM5抗體,Tusamitamab的類似物,其臨床研究主要探索單藥或聯(lián)合化療、免疫檢查點抑制劑在晚期實體瘤中的療效與安全性,尤其關(guān)注CEACAM5陽性患者的治療響應及生存獲益。CEACAM5作為腫瘤相關(guān)抗原,在結(jié)直腸癌、胃癌、非小細胞肺癌等上皮源性腫瘤中高表達,是重要的治療靶點。Tusamitamab通過特異性結(jié)合CEACAM5,可阻斷其介導的細胞黏附與信號傳導,抑制腫瘤細胞增殖、侵襲及轉(zhuǎn)移,同時可能通過抗體依賴的細胞介導的細胞毒性作用(ADCC)和補體依賴的細胞毒性作用(CDC)增強抗腫瘤免疫應答。 該抗體憑借對食蟹猴的種屬交叉反應性,成為轉(zhuǎn)化醫(yī)學研究的關(guān)鍵工具。研究者可利用食蟹猴模型評估藥物的藥代動力學特征、組織分布及長期毒性,為臨床給藥方案設(shè)計提供數(shù)據(jù)支持。此外,在基礎(chǔ)研究中,該抗體可用于檢測CEACAM5在腫瘤細胞系及組織樣本中的表達水平,探究其在腫瘤發(fā)生發(fā)展中的分子機制,助力新型聯(lián)合治療策略的開發(fā)。其高特異性和重組表達特性也確保了實驗結(jié)果的穩(wěn)定性與可重復性,推動腫瘤靶向治療的基礎(chǔ)與臨床轉(zhuǎn)化研究進展。
  • Uniprot No.:
  • 基因名:
  • 別名:
    Carcinoembryonic antigen antibody; Carcinoembryonic antigen-related cell adhesion molecule 5 antibody; CD66e antibody; CEA antibody; Ceacam5 antibody; CEAM5_HUMAN antibody; DKFZp781M2392 antibody; Meconium antigen 100 antibody; OTTHUMP00000199032 antibody; OTTHUMP00000199033 antibody; OTTHUMP00000199034 antibody
  • 反應種屬:
    Human
  • 免疫原:
    Recombinant Human CEACAM5 protein
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    0.01M PBS,pH7.4
  • 產(chǎn)品提供形式:
    Liquid
  • 應用說明:
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    In stock
  • 用途:
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能:
    Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells.; (Microbial infection) Receptor for E.coli Dr adhesins. Binding of E.coli Dr adhesins leads to dissociation of the homodimer.
  • 基因功能參考文獻:
    1. Positive CEA mRNA in low rectal cancer is a factor that predisposes patients to a high risk for overall recurrence, especially for local recurrence. PMID: 28291565
    2. High carcinoembryonic antigen elevation is associated with recurrence in rectal cancer. PMID: 29774483
    3. CEA and CA19-9 are cancer antigens that are late markers of carcinogenesis, with significantly elevated serum concentrations in case of colon cancer with already developed metastases. Older age group of patient has significantly elevated levels of both antigens. Cancer was twice more common in men than in women. PMID: 25568506
    4. High CEA expression is associated with breast cancer metastasis. PMID: 29433529
    5. Pretreatment serum CEA levels over 30.02 ng/mL on behalf of worse characteristics and unfavourable tumor behavior, and a poor prognosis for a nearly doubled risk of mortality in gastric cancer patients. PMID: 29358864
    6. Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer. PMID: 29121872
    7. The elevation of serum CEA level was independent from the other tumor markers in hypohidrotic condition represented by acquired idiopathic generalized anhidrosis. PMID: 28295553
    8. Elevated CEA levels during targeted therapy may be a more sensitive predictor of explosive lung adenocarcinoma progression in patients harboring mutant EGFRs compared to traditional imaging methods. PMID: 28705152
    9. Increased CEA expression is associated with colorectal cancer. PMID: 28128739
    10. The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively. PMID: 29247745
    11. In patients with non-small-cell lung cancer treated with nivolumab, worse pretreatment performance status, and higher carcinoembryonic antigen were associated with inferior progression-free survival. PMID: 29277824
    12. To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab PMID: 27234640
    13. This is the first population-based investigation of a large cohort of exclusively stage I rectal cancer patients providing compelling evidence that elevated preoperative CEA level is a strong predictor of worse overall and cancer-specific survival. PMID: 27067235
    14. Elevated levels of systemic IFNgamma and IL-6 implied that the CEACAM5-specific T cells had undergone immune activation in vivo but only in patients receiving high-intensity pre-conditioning. PMID: 28660319
    15. Combination of the two tumor markers, CEA and CYFRA21-1, is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients PMID: 28870944
    16. Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully. PMID: 28870949
    17. Postoperative CEA level >2.5 ng/ml is a predictor of distant metastasis and a negative prognostic factor for survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery. PMID: 27553616
    18. Data show that triple-negative breast cancer (TNBC) patients with pre-therapeutic serum high levels of both carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) had shorter overall survival (OS) and disease-free survival (DFS) rates than those in the low-level groups. PMID: 27561099
    19. Serum CEA level is not influenced by the presence of benign dominant biliary stricture or superimposed bacterial cholangitis in patients with primary sclerosing cholangitis. PMID: 27943017
    20. Preoperative-CEA was elevated (>/=5.0 ng/mL) in 73.6% of the colorectal cancer patients and remained elevated after surgery in 32.7% of the patients. Elevated postoperative-CA 19-9 (>/=50 U/mL) was observed in 9.5% of the patients. Neither elevated pre-CEA nor elevated pre-CA 19-9 was associated with relapse-free survival (RFS) but both elevated post-CEA and elevated post-CA 19-9 were associated with reduced RFS. PMID: 27664887
    21. the diagnostic sensitivity and specificity of serum reactive oxygen species modulator 1 were only 41.38% and 86.21%, respectively, with the cutoff value of 27.22 ng/mL. The sensitivity and specificity of pleural fluid carcinoembryonic antigen were 69.23% and 88.00%, respectively, at the cutoff value of 3.05 ng/mL, while serum carcinoembryonic antigen were 80.77% and 72.00% at the cutoff value of 2.60 ng/mL. PMID: 28459208
    22. Taken together, the results of our study identified CEACAM5 as a novel cell surface binding target of Middle East respiratory syndrome coronavirus that facilitates infection by augmenting the attachment of the virus to the host cell surface. PMID: 27489282
    23. Data show that carcinoembryonic antigen (CEA) modestly differentiated between mucinous and nonmucinous lesions, and amylase did not distinguish intraductal papillary mucinous neoplasms (IPMNs) from mucinous cystadenomas (MCAs). PMID: 26646270
    24. In this study, we detected the tumor marker carcinoembryonic antigen (CEA) using the QD-LFTS system, which allowed quantitative analysis in the range of 1-100ng/mL with an ideal detection limit of 0.049ng/mL. Thus, the system is suitable for detecting CEA in the clinically accepted range. We also detected 70 positive and 30 negative serum samples using the Handing system, which exhibited good specificity and sensitivity. PMID: 27825889
    25. As a proof-of-concept study, the constructed platform exhibits good specificity for CEA and the detection limit reaches as low as 8pg/mL (45 fM) with a wide linear range from 0.01 to 60ng/mL in the both cases PMID: 27886601
    26. Under the optimal conditions, the proposed immunosensor was used for the detection of CEA with wide dynamic range in the range from 5 fg/mL to 50ng/mL with a low detection limit of 2fg/mL (S/N=3). PMID: 27871047
    27. Relative CL intensity of all-in-one dual-aptasensor, operated with the competitive reaction of CEA and hemin in the presence of the dual aptamer, was exponentially decreased with the increase of CEA concentration in human serum PMID: 27875751
    28. Data indicate that serum tumor markers showed significant shorter 3-year progression-free survival (PFS) in higher levels compared to lower levels for S-CYFRA 21-1 (cytokeratin 19 fragment), S-SCCA and S-CEA. PMID: 26432331
    29. Multivariate logistic regression analysis revealed TC and DeltaCEA as independent factors in predicting TRG; TC showed a sensitivity of 62.79 %, a specificity of 91.49 %, a Youden index of 0.543, a cutoff value of 5.52, and an AUC of 0.800 compared with DeltaCEA (sensitivity 76.74 %, specificity 65.96 %, Youden index 0.427, and AUC 0.761). PMID: 26531721
    30. Data suggest that joint detection of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) and carcinoembryonic antigen (CEA) can improve the diagnostic sensitivity and specificity. PMID: 26438059
    31. High CEA level is associated with Oral Squamous Cell Carcinoma. PMID: 27165212
    32. High CEA expression is associated with metastasis and recurrence in endometrial cancer. PMID: 26779635
    33. ZKSCAN3 appears to promote colorectal tumor progression and invasion. ZKSCAN3 may facilitate hepatic metastasis of CRC associated with CEA particularly in cases with CEA-producing tumor PMID: 27127149
    34. we evaluated the clinical performance of LOCItrade mark-based tumor marker assays CEA, CA19-9, CA15-3, CA125 and AFP in patients with gastrointestinal cancer and demonstrated their high diagnostic power PMID: 28011514
    35. High carcinoembryonic Antigen expression is associated with gastric cancer. PMID: 25124614
    36. High CEA expression is associated with Squamous cell carcinoma of the skin. PMID: 27039776
    37. Preparation of Au-polydopamine functionalized carbon encapsulated FeO magnetic nanocomposites and their application for ultrasensitive detection of carcino-embryonic antigen. PMID: 26868035
    38. Elevated Carcinoembryonic Antigen Levels are associated with Colon Cancer. PMID: 26759308
    39. Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in non-small cell lung cancer patients harboring EGFR mutations. PMID: 27072247
    40. BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF. PMID: 27072263
    41. Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development. PMID: 27072222
    42. We conclude that patients with high preoperative serum CEA levels should have more intensive follow-up for detection of synchronous liver metastasis. PMID: 26756614
    43. Elevated CEA expression is associated with Gastric Cancer. PMID: 26620645
    44. CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer PMID: 26560853
    45. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. PMID: 26892612
    46. combined pre-chemoradiotherapy CEA and post-chemoradiotherapy CEA levels enable more accurate prediction of rectal adenocarcinoma prognosis PMID: 26962798
    47. ESCC patients with lower Cyfra21-1 and CEA, higher miR-7 and severe myelosuppression were much more sensitive to CRT. PMID: 26708917
    48. Cyst fluid CEA levels have a clinically suboptimal accuracy level in differentiating pancreatic mucinous cystic neoplasms from pancreatic nonmucinous cystic neoplasms. PMID: 26077458
    49. High carcinoembryonic antigen expression is associated with Colon Adenomas. PMID: 27100181
    50. Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable. PMID: 26333429

    顯示更多

    收起更多

  • 亞細胞定位:
    Cell membrane; Lipid-anchor, GPI-anchor. Apical cell membrane. Cell surface.
  • 蛋白家族:
    Immunoglobulin superfamily, CEA family
  • 組織特異性:
    Expressed in columnar epithelial and goblet cells of the colon (at protein level). Found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon.
  • 數(shù)據(jù)庫鏈接:

    HGNC: 1817

    OMIM: 114890

    KEGG: hsa:1048

    STRING: 9606.ENSP00000221992

    UniGene: Hs.709196



×